We are live on ! Find out more
OM

Opaleye Management Portfolio holdings

AUM $1.1B
1-Year Est. Return 197.64%
This Fund
S&P 500
This Quarter Est. Return
+9.36%
1 Year Est. Return
+197.64%
3 Year Est. Return
+748.31%
5 Year Est. Return
+1,163.14%
10 Year Est. Return
+87,953.74%
AUM
$377M
AUM Growth
-$132M
Cap. Flow
-$52M
Cap. Flow %
-13.79%
Top 10 Hldgs %
59.97%
Holding
58
New
11
Increased
13
Reduced
12
Closed
14

Top Buys

Rank Stock Value
1
TARA icon
Protara Therapeutics
TARA
+$64.2M
2
ETON icon
Eton Pharmaceutcials
ETON
+$12.7M
3
MTEM
Molecular Templates, Inc.
MTEM
+$7.79M
4
MYOV
Myovant Sciences Ltd.
MYOV
+$7.36M
5
KALA icon
KALA BIO
KALA
+$5M

Top Sells

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$34.1M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$21.2M
3
BOLD
Audentes Therapeutics, Inc
BOLD
+$17.5M
4
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$13.9M
5
AXGN icon
Axogen
AXGN
+$12.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.07%
2 Miscellaneous 1.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITCI
51
DELISTED
Intra-Cellular Therapies Inc.
ITCI
– –
-406,600
Closed -$13.9M
TPTX
52
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-340,500
Closed -$21.2M
EPZM
53
DELISTED
Epizyme, Inc
EPZM
– –
-1,384,200
Closed -$34.1M
RARX
54
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
– –
-141,800
Closed -$6.66M
ACHN
55
DELISTED
Achillion Pharmaceuticals
ACHN
– –
-760,000
Closed -$4.58M
BOLD
56
DELISTED
Audentes Therapeutics, Inc
BOLD
– –
-292,000
Closed -$17.5M
BHVN
57
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
– –
-165,000
Closed -$8.98M
1 2
3

Similar funds

CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
PFM
Premier Fund Managers Guildford, United Kingdom $1.1B AUM 14.42% 1-Year Est. Return
HBCM
Heron Bay Capital Management Bloomfield Hills, Michigan $1.1B AUM 11.31% 1-Year Est. Return
HAS
HBW Advisory Services Simi Valley, California $1.11B AUM 25.66% 1-Year Est. Return
AI
Aperture Investors New York $1.11B AUM 81.44% 1-Year Est. Return
TPA
Trivium Point Advisory Westport, Connecticut $1.1B AUM 28.81% 1-Year Est. Return
ZDA
Zweig-DiMenna Associates New York $1.1B AUM 171.86% 1-Year Est. Return
NW
Naviter Wealth Little Rock, Arkansas $1.1B AUM 33.28% 1-Year Est. Return

Opaleye Management's Q1 2020 Portfolio in Review

As of Q1 2020, Opaleye Management held 58 positions worth $377M, down 26% from $510M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Opaleye Management withdrew a net $52M in Q1 2020, closing 14 positions and reducing 12 holdings. Its most notable exit was Epizyme, Inc, an estimated $34.1M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, Opaleye Management opened a new position in Molecular Templates, Inc. worth $7.09M.

  • Opaleye Management's largest Q1 2020 buy was Molecular Templates, Inc.: 35,560 shares worth $7.09M.
  • Opaleye Management added most to Protara Therapeutics in Q1 2020, an estimated $64.2M increase.
  • Opaleye Management's biggest Q1 2020 reduction was Forty Seven, Inc. Common Stock, cutting an estimated $10.7M.
  • Opaleye Management fully exited Epizyme, Inc in Q1 2020, selling an estimated $34.1M.
  • Opaleye Management's ten largest holdings make up 60% of its $377M portfolio in Q1 2020.
  • Opaleye Management opened 11 new positions and closed 14 in Q1 2020.
  • Opaleye Management's portfolio value fell 26% quarter-over-quarter to $377M.

Based on Opaleye Management's 13F filing for Q1 2020, filed 15 May 2020.